These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23101153)

  • 41. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
    Laverman G; Ruggenenti P; Remuzzi G
    Curr Hypertens Rep; 2003 Oct; 5(5):364-7. PubMed ID: 12948427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension.
    Opie LH
    Lancet; 2001 Dec; 358(9296):1829-31. PubMed ID: 11741617
    [No Abstract]   [Full Text] [Related]  

  • 44. [Diabetic nephropathy].
    Haneda M
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():260-9. PubMed ID: 12430239
    [No Abstract]   [Full Text] [Related]  

  • 45. Angiotensin receptor blockers do not have an advantage over angiotensin-converting inhibitors [corrected].
    Harman-Boehm I
    Isr Med Assoc J; 2004 May; 6(5):296-8. PubMed ID: 15151373
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
    He D; Zhang Y; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Horm Metab Res; 2020 May; 52(5):289-297. PubMed ID: 32219798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diabetic nephropathy: evidence for renoprotection and practice.
    Mogensen CE
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i26-8:discussion i50. PubMed ID: 10956317
    [No Abstract]   [Full Text] [Related]  

  • 49. Current practices in the management of diabetic nephropathy.
    Chan G; Tang SC
    J R Coll Physicians Edinb; 2013; 43(4):330-2; quiz 333. PubMed ID: 24350318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antihypertensive treatment in the type 2 diabetic].
    Fournier A
    Nephrologie; 2000; 21(4):203-4. PubMed ID: 10976435
    [No Abstract]   [Full Text] [Related]  

  • 51. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diabetes and hypertension].
    Sayk F; Iwen KA; Lehnert H
    Dtsch Med Wochenschr; 2009 Nov; 134(45):2296-301. PubMed ID: 19876807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
    Catalá-López F
    Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes.
    Shani M; Vinker S; Feldman L
    J Clin Hypertens (Greenwich); 2017 Jun; 19(6):627-631. PubMed ID: 28177196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Compelling drug indications in diabetic and nondiabetic nephropathy.
    Ritz E; Dikow R; Zeier M
    Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Early diagnosis and therapy of diabetic nephropathy].
    Shigeta Y
    Nihon Naika Gakkai Zasshi; 1996 Mar; 85(3):464-7. PubMed ID: 8691016
    [No Abstract]   [Full Text] [Related]  

  • 60. Prevention of diabetic nephropathy.
    Materson BJ; Preston RA
    Hosp Pract (1995); 1997 Feb; 32(2):129-34, 139-40. PubMed ID: 9040425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.